Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

Johnson, Matthew GMatthew GJohnsonStrizki, Julie MJulie MStrizkiBrown, Michelle LMichelle LBrownWan, HongHongWanShamsuddin, Hala HHala HShamsuddinRamgopal, MotiMotiRamgopalFlorescu, Diana FDiana FFlorescuDelobel, PierrePierreDelobelKhaertynova, IlsiyarIlsiyarKhaertynovaFlores, José FJosé FFloresFouche, Leon FLeon FFoucheSHAN-CHWEN CHANGWilliams-Diaz, AngelaAngelaWilliams-DiazDu, JiejunJiejunDuGrobler, Jay AJay AGroblerPaschke, AmandaAmandaPaschkeDe Anda, CarisaCarisaDe Anda2023-02-142023-02-142023-01-1703008126https://scholars.lib.ntu.edu.tw/handle/123456789/628037Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial.enCOVID-19; Immunocompromised; Molnupiravir; Treatment; VirologyMolnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialjournal article10.1007/s15010-022-01959-9366486272-s2.0-85146386136https://api.elsevier.com/content/abstract/scopus_id/85146386136